Imvotamab

N/A

Report date: 2026/03/19 16:46:28

Base Information

Drug NameImvotamab

Drug Alias NameIGM-2323

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3CD20-directed cytolytic effectsAnti-CD20

TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD20

Therapy Area/IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicLupus Erythematosus, Cutaneous +[11]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaUnited StatesPoland +[8]

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesIgm Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesIgm Biosciences Inc

Active IndicationsN/A

Inactive IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicLupus Erythematosus, Cutaneous +[11]

Other Information

ATC CodeN/A